Small Stocks, Big Money™

GreenPower (Nasdaq: GP) delivered the first four of 50 purpose-built, all-electric BEAST school buses under an $18.6M EPA Clean School Bus Program grant, showcasing its leadership in U.S.-manufactured zero-emission transportation. With more deliveries underway and production based in South Charleston, GreenPower is powering the electrification of student transit across a $40B+ U.S. school bus market, combining cutting-edge design with rapid, federally supported deployment.

Can-Fite (NYSE American: CANF) is set to unlock major veterinary market value as partner Vetbiolix launches an advanced clinical trial of Piclidenoson for canine osteoarthritis. With projected peak sales of $445M and a potential 6% market share, Can-Fite expects to generate $325M in royalties and milestone payments by 2035—leveraging Piclidenoson’s strong safety profile as a next-gen, orally administered alternative to current NSAIDs and injectables in a fast-growing $6.3B market.

XTI Aerospace (Nasdaq: XTIA) has authorized a $5 million share buyback, signaling confidence in its long-term growth as it advances the TriFan 600—its innovative VTOL business aircraft—and expands its real-time location tech solutions. With just 3.7 million shares outstanding, the move highlights management’s commitment to enhancing shareholder value and reflects belief in the company’s strategic trajectory.

Greenwich LifeSciences (Nasdaq: GLSI) announced that early safety data from its Phase III FLAMINGO-01 trial of GLSI-100 immunotherapy shows no serious adverse events and mirrors the strong safety profile seen in its prior Phase IIb study, which demonstrated an 80%+ reduction in breast cancer recurrence. With enrollment accelerating and no DSMB-recommended changes, GLSI-100 continues to show promise as a well-tolerated, immune-boosting therapy targeting HER2+ breast cancer.